https://charts.traderzeitung.de/phases/CA29842P1053
string(1379) "{"isin":"CA29842P1053","name":"Eupraxia Pharmaceuticals Inc","stock_id":43043392,"generated_at":"2026-10-11 02:20:00","days":[{"date":"2026-10-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.785,"close_at":"2026-10-07 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-08","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.58,"close_at":"2026-10-08 21:59:00","complete":true,"perf_pct":-2.6333},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-10-09","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":7.46,"close_at":"2026-10-09 21:59:00","complete":true,"perf_pct":-1.5831},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Eupraxia Pharmaceuticals Aktie News & Nachrichten
Trading-Room

Eupraxia Pharmaceuticals Aktie News & Nachrichten

[WKN: A3EGRS | Symbol: EPRX]
Realtimekurs
   
Eupraxia Pharmaceuticals, Inc. operates as a drug delivery technology company in Canada. It delivers drugs into body compartments, such as the joint without any of the common issues with body compartment injections, such as systemic exposure. The firm focuses on arthritis, diabetic macular edema, and chronic pain programs. The company was founded by James A. Helliwell and John Salvatore Montalbano on May 12, 2011 and is headquartered in Victoria, Canada.
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel
Trader-Zeitung Agents
Agentische Berichterstattung zu Eupraxia Pharmaceuticals
Kursziele und Analysen
Analystenmeinungen zu Eupraxia Pharmaceuticals

Artikel aus der Redaktion der Trader-Zeitung

Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals: Wie gezielte Wirkstofffreisetzung Milliardenmärkte adressiert – Oppenheimer sieht massives Kurspotenzial

Von der systemischen zur lokalen Therapie: Das Geschäftsmodell Eupraxia Pharmaceuticals Inc. (EPRX)...

Eupraxia Pharmaceuticals Inc. (EPRX): Cantor Fitzgerald sieht 108 % Kurspotenzial!

Momentan fällt eine Eupraxia Pharmaceuticals Inc. (EPRX) positiv auf. Der Biotech hat sich auf die...

TOP-5-Kursziele der Analysten am 24.07.25

AxoGen Inc. [US05463X1063] Lake Street bestätigt Buy-Rating mit Kursziel 30 USD (123 % Kurspotenzial)...

  • ‹
  • 1
  • ›
Eupraxia Pharmaceuticals Nachrichtenticker öffnen
MT Newswires 24.09.2026 13:05 Uhr

Wedbush stuft Eupraxia Pharmaceuticals mit Outperform und einem Kursziel von 17 USD ein

07:04 AM EDT, 09/24/2026 (MT Newswires) -- Eupraxia Pharmaceuticals (EPRX) hat laut von FactSet befragten Analysten ein durchschnittliches Rating von

MT Newswires 28.07.2026 13:30 Uhr

Größte Verlierer im vorbörslichen Handel

07:29 AM EDT, 28.07.2026 (MT Newswires) -- Die Aktien von FiEE (FIEE) gaben im vorbörslichen Handel am Dienstag um 20 % nach, nachdem sie in der vorhe